7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A complete guide to pioglitazone's FDA approval history, compounding legal status, label requirements, and post-market safety data. prepared by the HealthRX.com Editorial Team.
A detailed comparison of how the FDA and EMA have regulated pioglitazone (Actos), including label differences, bladder cancer warnings, cardiovascular data, and post-market safety decisions.
Complete FDA approval history of pioglitazone (Actos), including original 1999 approval, black box warnings, bladder cancer reviews, and current prescribing label status.
A detailed review of pioglitazone's regulatory history across the FDA, EMA, and other global agencies, including approval timelines, label changes, safety communications, and current prescribing status.
A review of pioglitazone (Actos) label content and FDA safety communications relevant to prescribing decisions from 2020 through 2026, covering bladder cancer language, heart failure warnings, bone fracture risk, and off-label NASH/MASH use, with explicit flags where source figures require independent verification.
A complete clinical and regulatory guide to pioglitazone (Actos): FDA approval timeline, patent litigation, label updates, post-market safety findings, and what the evidence means for prescribers and patients.
A clinical review of pioglitazone's FDA approval history, current label, post-market safety surveillance, and the next-generation thiazolidinedione pipeline including MSDC-0602K and seladelpar.